2010年，上市许可申请数据下降的药品包含新药和仿制药，仿制药在完成申请方面下降特别明显。
For 2010, the decline in MA applications encompasses both new products and generics and is particularly marked in finalized applications.
第三条委托方应是持有该加工药品境外上市许可或销售许可的制药厂商或其委托代理人。
Article 3 an entrusting party shall be a pharmaceutical manufacturer holding the permit for listing or selling the processed drug abroad or serve as its authorized agent.
第三条委托方应是持有该加工药品境外上市许可或销售许可的制药厂商或其委托代理人。
Article 3 an entrusting party shall be a pharmaceutical manufacturer holding the permit for listing or selling the processed drug abroad or serve as its authorized agent.
应用推荐